Richard E. Gammans

2.0k total citations
42 papers, 1.6k citations indexed

About

Richard E. Gammans is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, Richard E. Gammans has authored 42 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 8 papers in Molecular Biology and 8 papers in Pharmacology. Recurrent topics in Richard E. Gammans's work include Analytical Chemistry and Chromatography (7 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Richard E. Gammans is often cited by papers focused on Analytical Chemistry and Chromatography (7 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Richard E. Gammans collaborates with scholars based in United States, Germany and Belgium. Richard E. Gammans's co-authors include Robert F. Mayol, LuAnn Sabounjian, John A. Labudde, Wayne M. Clark, L. Creed Pettigrew, Rajesh C. Shrotriya, Steven Warach, Benjamin J. Williams, Donald R. Alms and Donald S. Robinson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Analytical Chemistry.

In The Last Decade

Richard E. Gammans

42 papers receiving 1.5k citations

Peers

Richard E. Gammans

EPIDE

NEURO

CMN

PHARM

Antonio Capurso Italy

Roger Desnyder Belgium

Carlos Perdomo United States

Pietro Gareri Italy

Carlo Masullo Italy

Aaron Koenig United States

Yu-Hui Liu China

Finn Bengtsson Sweden

Verna R. Porter United States

Manuela Contin Italy

Antonio Capurso Italy

Richard E. Gammans

161 ×0.4

EPIDE

335 ×1.0

NEURO

383 ×1.5

115 ×0.5

CMN

106 ×0.5

PHARM

Citations per year, relative to Richard E. Gammans Richard E. Gammans (= 1×) peers Antonio Capurso

Countries citing papers authored by Richard E. Gammans

Since Specialization

Citations

This map shows the geographic impact of Richard E. Gammans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Gammans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Gammans more than expected).

Fields of papers citing papers by Richard E. Gammans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Gammans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Gammans. The network helps show where Richard E. Gammans may publish in the future.

Co-authorship network of co-authors of Richard E. Gammans

This figure shows the co-authorship network connecting the top 25 collaborators of Richard E. Gammans. A scholar is included among the top collaborators of Richard E. Gammans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard E. Gammans. Richard E. Gammans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Traynor, Anne M., Michael S. Gordon, Dona Alberti, et al.. (2009). A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Investigational New Drugs. 28(4). 509–515. 14 indexed citations

Sarantopoulos, John, et al.. (2006). 359 POSTER Pharmacokinetic and pharmacodynamic effects of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 111–112. 1 indexed citations

Warach, S., L. Creed Pettigrew, John F. Dashe, et al.. (2000). Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging. Annals of Neurology. 48(5). 713–722. 7 indexed citations

Clark, Wayne M., et al.. (1997). A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 49(3). 671–678. 177 indexed citations

Barbhaiya, Rashmi H., Umesh Shukla, M Pfeffer, et al.. (1994). Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. European Journal of Clinical Pharmacology. 46(1). 41–7. 21 indexed citations

Shyu, Wen Chyi, Robert F. Mayol, Morris Pfeffer, et al.. (1993). Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharmaceutics & Drug Disposition. 14(5). 371–379. 29 indexed citations

Gammans, Richard E., et al.. (1992). NEFAZODONE EFFICACY IN SEVERE DEPRESSION. Clinical Neuropharmacology. 15. 332B–332B. 1 indexed citations

Robinson, Donald S., Karl Rickels, John P. Feighner, et al.. (1990). Clinical Effects of the 5-HT1A Partial Agonists in Depression. Journal of Clinical Psychopharmacology. 10(Supplement). 67S–76S. 140 indexed citations

Stallone, Frank, et al.. (1990). A Double-Blind Comparison of Buspirone, Clobazam, and Placebo in Patients with Anxiety Treated in a General Practice Setting. Journal of Clinical Psychopharmacology. 10(Supplement). 38S–42S. 23 indexed citations

10.

Robinson, Donald S., et al.. (1990). Buspirone Therapy in Anxious Elderly Patients. Journal of Clinical Psychopharmacology. 10(Supplement). 47S–51S. 64 indexed citations

11.

Gammans, Richard E., et al.. (1989). Pharmacokinetics of Buspirone in Elderly Subjects. The Journal of Clinical Pharmacology. 29(1). 72–78. 28 indexed citations

12.

Caccia, Silvio, G. Mingardi, Silvio Garattini, et al.. (1988). Clinical Pharmacokinetics of Oral Buspirone in Patients with Impaired Renal Function. Clinical Pharmacokinetics. 14(3). 171–177. 16 indexed citations

13.

Bartek, M.J., et al.. (1988). Analysis of Encainide and Metabolites in Plasma and Urine by High-Performance Liquid Chromatography. Therapeutic Drug Monitoring. 10(4). 446–452. 2 indexed citations

14.

Dischino, Douglas D., et al.. (1988). Synthesis of tetradeuterated buspirone. Journal of Labelled Compounds and Radiopharmaceuticals. 25(4). 359–367. 4 indexed citations

15.

Kerns, Edward H., William W. Bullen, & Richard E. Gammans. (1986). Quantitative analysis of 1-(2-pyrimidinyl)piperazine in plasma by capillary gas chromatography—mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 377. 195–203. 12 indexed citations

16.

Gammans, Richard E., et al.. (1985). The relationship between buspirone bioavailability and dose in healthy subjects. Biopharmaceutics & Drug Disposition. 6(2). 139–145. 27 indexed citations

17.

Roden, Dan M., Stots B. Reele, Stanley B. Higgins, et al.. (1980). Total Suppression of Ventricular Arrhythmias by Encainide. New England Journal of Medicine. 302(16). 877–882. 133 indexed citations

18.

Gammans, Richard E., et al.. (1977). Microsomal N-hydroxylation of trans-4'-halo-4-acetamidostilbenes.. Drug Metabolism and Disposition. 5(3). 310–316. 7 indexed citations

19.

Sternson, Larry A. & Richard E. Gammans. (1975). INTERACTION OF AROMATIC NITRO COMPOUNDS WITH REDUCED HEPATIC MICROSOMAL CYTOCHROME P-450. Drug Metabolism and Disposition. 3(4). 266–274. 8 indexed citations

20.

Stewart, James T. & Richard E. Gammans. (1975). Synthesis and Biological Evaluation of 2‐(9‐Acridinyl) ethyl‐N‐substituted Carbamates and Their Hydrochlorides and 10‐N‐Oxides. Journal of Pharmaceutical Sciences. 64(6). 1061–1063. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact